Mayoly has completed the divestment of several non-strategic brands to Zentiva, an international pharmaceutical company. The transaction covers brands marketed in France as well as in Central and Eastern Europe.

 

As of 30 June 2026, Zentiva has become the new owner of the following brands: Baume Aroma, Aroma Poche, Aroma Patch, Prontalgine, Prontadol, Paxeladine, Buscopan and Suppositoria Glycerini. Together, these brands represent approximately 2% of Mayoly’s revenue. Mayoly will continue to manufacture Paxeladine and Prontadol.

 

This transaction is fully aligned with Mayoly’s strategy to streamline its brand portfolio and strengthen its investment capacity. The objective is to support the development of our priority therapeutic areas and create opportunities for future growth.

 

A big thank you to all the teams who contributed to the success of this transaction, and especially to our colleagues in Mergers & Acquisitions, Strategy Innovation & Transformation Business, Legal, Finance, Manufacturing & Supply Chain, and Regulatory Affairs. Their commitment, expertise and collaboration were instrumental throughout the project.

No comments yet, be the first to comment.

Deja una respuesta